Browsing Tag
FDA
293 posts
Senti Biosciences gets FDA orphan drug status for SENTI-202 in relapsed AML treatment
Senti Biosciences earns FDA orphan drug designation for SENTI-202 in AML. Find out how this logic-gated CAR-NK therapy could reshape leukemia treatment.
Gadoquatrane heads to FDA: Can Bayer lead the next generation of low-dose MRI contrast agents?
Bayer targets FDA nod for gadoquatrane, the lowest‑dose macrocyclic MRI contrast agent, potentially reshaping radiology practices globally.
CERo Therapeutics gets FDA boost for CER-1236, eyes breakthrough in AML cell therapy
CERo Therapeutics secures FDA orphan drug status for CER-1236 in AML, advancing its novel CER-T immunotherapy platform. Read what this means for investors.
Merck (NASDAQ: MRK) wins FDA approval for ENFLONSIA to prevent RSV in infants
FDA clears Merck’s ENFLONSIA (NASDAQ: MRK) for RSV prevention in infants. See trial data, stock reaction, pediatric market impact & analyst projections.
Is EPG the ingredient food giants have been waiting for?
Discover how EPG is helping big food companies reformulate products quietly—cutting calories without changing taste or triggering consumer backlash.
EPG vs Olestra vs MCT Oil: Which fat alternative wins on taste, safety, and science?
Which fat substitute delivers on health, taste, and safety? Compare EPG, Olestra, and MCT oil as food companies reformulate for a healthier future.
Zai Lab and Novocure’s TTFields therapy shows survival benefit in pancreatic cancer: PANOVA-3 results unveiled at ASCO 2025
Zai Lab and Novocure report TTFields improves survival in pancreatic cancer. Read how ASCO 2025 results could reshape the standard of care.
CirCode Biomed’s HM2002 gets FDA green light: World’s first circular RNA drug to enter U.S. clinical trials for heart disease
CirCode’s HM2002 becomes the first circular RNA drug cleared by the FDA for clinical trials in ischemic heart disease—setting a precedent in RNA therapeutics.
How EPG is changing the science of fat reduction in food without sacrificing taste
EPG is a plant-based fat alternative reshaping food science by cutting calories without sacrificing taste. Learn how it's changing processed food formulations.
Fall 2025 COVID booster update: FDA endorses JN.1-based vaccine as dominant LP.8.1 strain spreads
FDA backs fall 2025 COVID booster targeting LP.8.1; rollout to begin by August. New vaccine expected to offer stronger protection against dominant variants.